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Background: Inverted papilloma (IP) of the nasal cavity is a benign tumor that represents
0.5–4% of all nasal tumors and have been known to rarely undergo malignant trans-
formation to squamous carcinoma and even more rarely adenocarcinoma. Synchronous
association with low-grade esthesioneuroblastoma (ENB) has been reported in only one
case report where a small-sized lesion was treated with surgery alone. Here we report the
first case of invasion of IP by high-grade ENB with nodal metastasis that was treated with
combined modality therapy.
Case Presentation: A case of a 64-year-old African American gentleman presented to the
otolaryngology with a 3-month history of recurrent epistaxis. Imaging revealed a large right
nasal cavity mass extending into the right sphenoid sinus but without intracranial exten-
sion. Surgical pathology revealed high-grade ENB invading IP. An orbitofrontal craniotomy
approach was used to achieve complete resection of the mass but with positive mar-
gins. Post-operative positron emission tomography/computed tomography showed nodal
metastasis. The patient was then treated with adjuvant chemoradiation and remains with-
out evidence of disease at 42 months post-treatment.We discuss the disease presentation,
histopathologic features, and disease management with literature support.
Conclusion: In this very rare disease presentation where two extremely rare malignancies
collide, we show that aggressive management with trimodality therapy of surgery, adjuvant
radiation with stereotactic radiosurgical boost, and adjuvant chemotherapy gives excellent
results. Given the natural history of the disease, however, long follow-up is needed to
declare complete freedom from the disease.
Keywords: inverted papilloma, esthesioneuroblastoma, skull base, collision tumor, sinonasal malignancy, head and
neck cancer
INTRODUCTION
Inverted papilloma (IP) of the nasal cavity is a benign but locally
aggressive, benign nasal lesion remarkable for its tendency for local
recurrence. These tumors represent 0.5–4% of all nasal tumors and
are associated with sinonasal squamous cell carcinoma in approx-
imately 5% of the cases and even more rarely adenocarcinoma (1).
Esthesioneuroblastoma (ENB) is another uncommon malignancy
of the head and neck, representing only 3–6% of all nasal cavity
and sinonasal neoplasms (2). It is a tumor of neural crest origin
that is believed to arise from the olfactory epithelium. Based on
the low incidence of ENB and IP, the odds of these two unrelated
tumors occurring in the same person in the same location are
exceedingly rare. In the existing literature, synchronous associa-
tion of IP with ENB has been reported in only one case report
where a small-sized lesion was treated with surgery alone (3). In
this paper, we present a case report of a collision of the high-grade
ENB with IP in a patient treated with definitive surgical resec-
tion with positive margins and post-operative findings of nodal
metastasis. He was treated with adjuvant chemoradiation followed
by stereotactic radiosurgery boost to high-risk disease. We discuss
disease presentation, pathological findings, and treatment strategy.
CASE PRESENTATION
A 64-year-old African American gentleman presented to otolaryn-
gology head and neck surgery clinic with a 3-month history of
recurrent epistaxis. On physical examination and nasal endoscopy,
the patient had a right nasal cavity mass. Computed tomography
(CT) revealed a right nasal cavity lesion extending into the eth-
moid and sphenoid sinuses. The mass was locally destructive, with
bony remodeling surrounding it. It measured 2.9 cm in the trans-
verse dimension by 3.9 cm in the cranial–caudal dimension by
6.6 cm in the anterior–posterior dimension. On MRI, the mass
obstructed the right sphenoid sinus with inspissated secretions
surrounding the mass (Figure 1). The mass extended up to the
cribriform plate but without evidence of intracranial extension or
orbital involvement. Nasal endoscopy (Figure 2) with debulking
www.frontiersin.org March 2014 | Volume 4 | Article 44 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Karam et al. Inverted papilloma with esthesioneuroblastoma
FIGURE 1 | MRI of esthesioneuroblastoma/inverted papilloma collision
tumor. Mass can be visualized in addition to inspissated secretions in the
surrounding sinuses.
FIGURE 2 | Nasal endoscopy view of collision tumor.
and biopsy revealed a high-grade malignant neoplasm adjacent to a
sinonasal papilloma with focal inverted growth pattern (Figure 3).
The tissue was negative for Epstein–Barr virus nuclear antigen-1
FIGURE 3 | Hematoxylin and eosin stain – high power of sinonasal
inverted papilloma with infiltration of epithelium by atypical cells
(esthesioneuroblastoma).
FIGURE 4 | Immunohistochemistry of lesion for synaptophysin
(characteristically stains positive in esthesioneuroblastoma).
(EBNA-1) by polymerase chain reaction (PCR) and Epstein–Barr
virus encoded RNA (EBRER) by immunohistochemistry. Further
immunohistochemical analysis showed the neoplastic cells to be
focally positive for pan-keratin, neuron-specific enolase (NSE),
synaptophysin (Figure 4), epithelial membrane antigen (EMA),
and vimentin. Additionally, rare immunoreactivity was noted in
the subepithelial tumor cells for chromogranin, neurofilament
(Figure 5), and GFAP. The specimen tested negative for leuko-
cyte common antigen (LCA), latent membrane protein (LMP),
S-100, CD20, CD3, desmin, and smooth muscle actin. The Ki-
67 proliferation index was reported at approximately 70%. The
immunohistochemical profile is consistent with a diagnosis of a
collision tumor of high-grade ENB with extensive involvement of
overlying schneiderian papilloma.
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FIGURE 5 | Immunohistochemistry of lesion for neurofilament stain
(characteristically stains positive in esthesioneuroblastoma).
TREATMENT
Surgical resection was performed via anterior and subfrontal cran-
iotomy. Sphenoid sinus disease was described to attach anteriorly
through the sphenoid ostium but without direct evidence of sphe-
noid mucosal disease. Complete surgical resection was reported.
Pathological examination, however, showed positive margins on
the superior border of the resection. Given this margin positiv-
ity and high-grade pathological features, the decision was made
to pursue adjuvant concomitant chemoradiation, which was ini-
tiated following his surgical recover at 9 weeks post-operatively.
Positron emission tomography (PET)/CT scan conducted for radi-
ation treatment planning revealed increased metabolic uptake
in the bilateral levels I and II neck nodes consistent with nodal
metastasis. His final stage was T2N1M0.
The determination of target volumes was based on pre-
operative and post-operative CT scans, 1 mm MRI images with
VIBE sequence, and thin sliced PET/CT complemented by clini-
cal and endoscopic information. The target volume included the
regions of high-risk and regions of lower-risk for microscopic
tumor spread. This consisted of the surgical bed with margins,
bilateral comprehensive lymph node volume levels 1–5 including
all PET positive disease, and the bilateral retropharyngeal lymph
node volumes. Using 6 mV photon energies, the plan was designed
with intensity modulated radiation therapy (IMRT) to improve
conformality and reduce dosage to critical structures. A prescrip-
tion was written for 28 fractions in 180 cGy each for a total dose
of 5040 cGy. Due to temporary machine malfunction during the
treatment, dose adjustment was made for 29, 180 cGy fractions
for a total dose of 5220 cGy. This was completed over a period of
6 weeks. Using stereotactic radiosurgery with Cyberknife (Accuray
Inc.), a reduced field was designed to the surgical bed and bilateral
retropharyngeal lymph node volumes in five fractions of 250 cGy
each. The bilateral PET positive levels I and II neck nodes were
then boosted with 6 mV photons with IMRT in five fractions of
250 cGy. The total cumulative dose was 6470 cGy. Figure 6 shows
a composite of his radiation treatment plan.
Concomitant chemotherapy included cisplatin (33 mg/m2)
and etoposide (100 mg/m2) for three cycles during weeks 1, 4,
and 7 of the radiation treatment. He suffered the expected toxicity
from the chemoradiation with intractable nausea, vomiting, grade
III mucositis, and dysphagia. He was treated symptomatically
but required two hospitalizations for failure to thrive and symp-
tom management. His pain was managed with patient-controlled
analgesia pump and for nutritional supplementation, total par-
enteral nutrition was initiated toward the end of his treatment.
On his 3-month visit following the end of his radiation treatment,
he had fully recovered from the rigors of the treatment. At his
42 months follow-up visit, his clinical examination and all of his
radiographic imaging studies including MRI and PET/CT were
without evidence of disease.
DISCUSSION
Inverted papillomas have been historically considered true neo-
plasms due to their locally aggressive nature and tendency for local
recurrence (4); new concepts in the pathogenesis of IPs suggest
that they may instead be an end stage of a chronic inflamma-
tory condition rather than a true neoplasm (5). It is estimated
that 11% of recurrent IPs undergo malignant transformation (6).
Human papillomavirus (HPV) serotypes 6, 11, 16, and 18 have
been detected in these lesions. Low risk serotypes 6 and 11 are
associated with benign papillomas; while serotypes 16 and 18
are associated with higher risk of malignant transformation and
recurrence (6).
Collision of IP with ENB is an extremely rare event. Synchro-
nous association has only been reported once in the literature
where IP collided with low-grade ENB in a case of less aggressive
disease presentation (3). ENBs are typically considered low-grade
tumors that respond well to treatment and immunohistochem-
ical confirmation has been recommended in cases of pathologic
findings of high-grade ENBs to avoid initial misdiagnosis and to
treat aggressively (7). IHC demonstrates that greater than 90%
of ENB cells are neuron-specific enolase positive. Approximately
80% of cases are positive for S-100, staining cell nests, and synapto-
physin (8). Cytokeratin AE1/AE3 and EMA are typically negative
with ENB (9). Unlike sinonasal undifferentiated carcinoma, ENB
demonstrates lesser pleomorphism, may contain smaller nucleoli,
and is EMA-negative and S-100 positive (10).
The diagnosis of a high-grade ENB has been shown to have a
significant impact on survival (7, 11, 12). In a retrospective review
by Dias and colleagues (13), the 5-year disease-specific survival
(DSS) for patients with low-grade tumors was 64%, whereas for
patients with high-grade tumors it was 43%. The importance of a
patient’s tumor histopathologic findings, as they relate to progno-
sis, vary among reports. Morita and colleagues (14) examined the
pathologic findings of 49 patients with ENB and noted the patho-
logic grade correlated with prognosis. Levine and colleagues (15)
found no valuable pathologic or molecular indicators to predict
aggressive clinical behavior in their series of patients. Recently,
however, comparative mutational genomic analysis of samples
taken from a patient with ENB at the time of initial presentation
and following recurrent metastatic disease showed new acquired
mutations in KDR, MYC, SIN3B, and NLRC4 genes with disease
progression (16). Kim et al. (17) examined 17 ENB specimens
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FIGURE 6 | (A–H) IMRT treatment plan with contoured target volume in axial, coronal, and sagittal view for the nasopharyngeal volume (A–D) and the
neck volumes (E–H). (I–L) Cyberknife treatment plan with the target volume in axial, coronal, and sagittal views.
for staining with bcl-2, p53, MIC-2, and N-myc. Of note, 70% of
specimens were positive for bcl-2. All specimens were negative for
N-myc. MIC-2 and p53 staining was noted in only one specimen.
The results suggested a potential survival advantage and improved
response to chemotherapy with bcl-2 positivity in patients with
ENB, yet this finding was not statistically significant.
Lymph node metastasis is also an important prognostic fac-
tor as the 5-year survival rate is 64% for node-negative dis-
ease compared to 29% for those with lymph node metastases
(2, 15, 18). Most series report that less than 15% of individu-
als present with regional nodal metastasis at the time of initial
evaluation (2, 15, 18). Zefereo et al. (19) noted that 22% their
patients were stage N1 at diagnosis. These series, however, are
based on clinical staging where most patients had not received
PET scanning. Wu and colleagues (20) showed ENB was PET
positive in seven of nine patients (77.7%) with a maximal stan-
dard uptake value (SUV max) of 6.37–4.22 in primary tumors.
Tracer uptake did not correlate with tumor size. PET/CT detected
regional metastases in two (cervical and parapharyngeal) patients
and distant metastases in four (lung, liver, and bone). PET/CT
altered the clinical staging in three of the nine patients. The
use of pretreatment PET/CT has also been advocated by other
authors (21).
The gold standard for treatment of ENB is a combination of
surgery and radiotherapy, with or without chemotherapy. Tumor
stage, histopathologic grade, and use of adjuvant radiation were
found to be important determinants of disease-free survival in a
meta-analysis examining 26 studies (from 1990 to 2000) with 390
patients (2). Adjuvant radiation dosing of 55 Gy or greater was
an additional variable found to be of prognostic value in a large
retrospective analysis that examined the outcomes of 77 patients
with non-metastatic ENB from the Rare Cancer Network (22).
Adjuvant radiation has been shown to improve local control after
surgery with a decrease in local recurrence rates from 71 to 17%, as
well as decrease the risk of regional recurrence (23). The timing of
radiation, before or after surgery, does not seem to impact the ben-
efit it offers to local disease control (24). Stereotactic radiation dose
escalation has been shown to yield excellent survival outcomes
without optical toxicity. Nichols and colleagues (25) reported on
the use of adjuvant proton beam radiation in 10 patients with
ENB with predominantly Kadish stage C disease. With a median
follow-up of 52.8 months, 5-year DFS and OS rates were 90 and
85.7%, respectively. In a more aggressive combination of proton
therapy with neoadjuvant chemotherapy, Fitzek and colleagues
also reported actuarial 5-year survival of 74% (26).
Chemotherapy has been generally accepted for patients with
ENB with high-grade, recurrent, or unresectable disease (27).
The combination of cisplatin and etoposide represents a popu-
lar regimen that has been successfully used in the neoadjuvant
and adjuvant setting. A review from the Mayo Clinic, involving 12
Frontiers in Oncology | Radiation Oncology March 2014 | Volume 4 | Article 44 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Karam et al. Inverted papilloma with esthesioneuroblastoma
patients with Kadish stage C high-grade ENB, examined the use of
adjuvant cisplatin and etoposide after complete surgical resection.
Six patients received adjuvant chemotherapy with radiation and
six received only post-operative radiation. The addition of adju-
vant chemotherapy improved median time to relapse from 10.5 to
35 months, yet did not significantly affect OS (28).
CONCLUSION
In this paper, we reported a very rare and unique pathologic
presentation of a collision of IP and ENB. The pathological
and immunohistochemical features were diagnostic of high-
grade ENB, which drove the clinical management of the disease.
The patient received complete surgical resection with adjuvant
chemoradiation for positive microscopic margins and high-grade
pathological features. Radiation dose escalation to areas of high-
risk disease was achieved with a combination of IMRT and
SBRT. At 42 months post-treatment, the patient remains without
evidence of disease. However, long term follow-up (>10 years)
remains the ultimate test in determining the success of this ther-
apy given the extended time to local and regional recurrence of
ENB (2).
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